Literature DB >> 12433063

Coregulators of estrogen receptor action.

Gilles B Tremblay1, Vincent Giguère.   

Abstract

The estrogen receptors are members of a large family of transcription factors, which include receptors for steroid hormones, retinoids, vitamin D and thyroid hormone, as well as several orphan receptors with yet undiscovered ligands. The process by which small lipophilic molecules signal in target tissues is complex and involves nuclear receptor associations with a multitude of coregulator proteins. These proteins participate in and recruit many enzymatic and structural activities that allow modulation of chromatin structure to facilitate stimulation or repression of gene expression. This review will present an overview of those regulatory factors that interact with the estrogen receptors and participate in the transmission of the estrogenic signal.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12433063     DOI: 10.1615/critreveukaryotgeneexpr.v12.i1.10

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  14 in total

Review 1.  Structure-nongenomic neuroprotection relationship of estrogens and estrogen-derived compounds.

Authors:  Laszlo Prokai; James W Simpkins
Journal:  Pharmacol Ther       Date:  2007-02-02       Impact factor: 12.310

Review 2.  Estrogens and prostate cancer: etiology, mediators, prevention, and management.

Authors:  Shuk-Mei Ho; Ming-Tsung Lee; Hung-Ming Lam; Yuet-Kin Leung
Journal:  Endocrinol Metab Clin North Am       Date:  2011-07-07       Impact factor: 4.741

Review 3.  Sex differences and sex steroids in lung health and disease.

Authors:  Elizabeth A Townsend; Virginia M Miller; Y S Prakash
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

4.  ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification.

Authors:  June X Zou; Alexey S Revenko; Li B Li; Abigael T Gemo; Hong-Wu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-12       Impact factor: 11.205

5.  The developmentally-regulated Smoc2 gene is repressed by Aryl-hydrocarbon receptor (Ahr) signaling.

Authors:  Peijun Liu; Dorothy E Pazin; Rebeka R Merson; Kenneth H Albrecht; Cyrus Vaziri
Journal:  Gene       Date:  2008-12-24       Impact factor: 3.688

6.  A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer.

Authors:  Dan Tian; Natalia M Solodin; Prashant Rajbhandari; Kelsi Bjorklund; Elaine T Alarid; Pamela K Kreeger
Journal:  FASEB J       Date:  2015-02-03       Impact factor: 5.191

7.  CAPER, a novel regulator of human breast cancer progression.

Authors:  Isabelle Mercier; Donna M Gonzales; Kevin Quann; Timothy G Pestell; Alexander Molchansky; Federica Sotgia; James Hulit; Ricardo Gandara; Chenguang Wang; Richard G Pestell; Michael P Lisanti; Jean-François Jasmin
Journal:  Cell Cycle       Date:  2014-02-17       Impact factor: 4.534

8.  MLL histone methylases regulate expression of HDLR-SR-B1 in presence of estrogen and control plasma cholesterol in vivo.

Authors:  Khairul I Ansari; Sahba Kasiri; Imran Hussain; Samara A Morris Bobzean; Linda I Perrotti; Subhrangsu S Mandal
Journal:  Mol Endocrinol       Date:  2012-11-28

9.  Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer.

Authors:  Wilbert Zwart; Vasiliki Theodorou; Marleen Kok; Sander Canisius; Sabine Linn; Jason S Carroll
Journal:  EMBO J       Date:  2011-10-14       Impact factor: 11.598

10.  Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer.

Authors:  Yuqing Li; Yi Li; Sara Wedrén; Guoliang Li; Tze Howe Charn; Kartiki Vasant Desai; Carine Bonnard; Kamila Czene; Keith Humphreys; Hatef Darabi; Kristjana Einarsdóttir; Tuomas Heikkinen; Kristiina Aittomäki; Carl Blomqvist; Kee Seng Chia; Heli Nevanlinna; Per Hall; Edison T Liu; Jianjun Liu
Journal:  Breast Cancer Res       Date:  2011-01-26       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.